We are live on ! Find out more
BEAM icon

Beam Therapeutics
BEAM

221 hedge funds and large institutions have $2.32B invested in Beam Therapeutics in 2024 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 80 increasing their positions, 47 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

206% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 18

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

70% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 47

19% more funds holding

Funds holding: 185 → 221 (+36)

17% more capital invested

Capital invested by funds: $1.99B → $2.32B (+$333M)

3.57% less ownership

Funds ownership: 89.71% → 86.14% (-3.6%)

53% less call options, than puts

Call options by funds: $13.8M | Put options by funds: $29.1M

Holders
221
Holders Change
+36
Holders Change %
+19.46%
% of All Funds
3.18%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
55
Increased
80
Reduced
47
Closed
18
Calls
$13.8M
Puts
$29.1M
Net Calls
-$15.4M
Net Calls Change
-$19.6M

Top Buyers

1
DGM
Darwin Global Management
Jersey
+$66M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$37.6M
3
BG
Bellevue Group
Switzerland
+$15.5M
4
RG
Redmile Group
California
+$14M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$12.9M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$132M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$40.1M
3
Temasek Holdings
Temasek Holdings
Singapore
-$39.4M
4
AIM
ARK Investment Management
Florida
-$37.8M
5
State Street
State Street
Massachusetts
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
ARK Investment Management
Florida
$270M -$37.8M -1,211,715 -13%
Vanguard Group
2
Vanguard Group
Pennsylvania
$250M +$12.9M +413,892 +6%
BlackRock
3
BlackRock
New York
$222M +$1.36M +43,583 +0.7%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$162M -$40.1M -1,285,869 -21%
FCM
5
Farallon Capital Management
California
$149M +$12.6M +406,000 +10%
Morgan Stanley
6
Morgan Stanley
New York
$136M -$132M -4,245,109 -51%
State Street
7
State Street
Massachusetts
$123M -$27.6M -885,166 -19%
Sumitomo Mitsui Trust Group
8
Sumitomo Mitsui Trust Group
Japan
$78M +$116K +3,726 +0.2%
NAMA
9
Nikko Asset Management Americas
New York
$77.9M +$116K +3,726 +0.2%
MM
10
MWG Management
British Virgin Islands
$77.5M – – –
DGM
11
Darwin Global Management
Jersey
$70M +$66M +2,119,598 New
RG
12
Redmile Group
California
$62.1M +$14M +449,834 +31%
Temasek Holdings
13
Temasek Holdings
Singapore
$59.9M -$39.4M -1,263,145 -41%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$54.1M +$1.91M +61,443 +4%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$41.2M +$37.6M +1,207,699 +3,138%
BG
16
Bellevue Group
Switzerland
$39.4M +$15.5M +498,300 +72%
YCM
17
Yiheng Capital Management
California
$27.9M – – –
Baillie Gifford & Co
18
Baillie Gifford & Co
United Kingdom
$24.9M -$365K -11,729 -2%
CC
19
Casdin Capital
New York
$22.3M +$4.58M +147,000 +28%
Northern Trust
20
Northern Trust
Illinois
$21.8M -$292K -9,362 -1%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$21.2M +$2.34M +75,003 +13%
Charles Schwab
22
Charles Schwab
California
$19.1M +$250K +8,036 +1%
Goldman Sachs
23
Goldman Sachs
New York
$18.2M +$2.12M +68,062 +14%
JP Morgan Chase
24
JP Morgan Chase
New York
$15.4M -$1.81M -57,947 -11%
Two Sigma Investments
25
Two Sigma Investments
New York
$11.9M +$11.2M +358,798 New
1
2 3 4 5

BEAM Hedge Fund Activity: Q1 2024 in Review

221 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2024, worth a combined $2.32B — up 17% from $1.99B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new BEAM positions and 18 closed out — a net gain of 37 holders — while 80 added to existing stakes and 47 trimmed.

The largest buyer was Darwin Global Management, opening a new position worth an estimated $66M. The largest seller was Morgan Stanley, cutting an estimated $132M.

  • 221 institutional investors held Beam Therapeutics (BEAM) as of Q1 2024, up from 185 in Q4 2023.
  • Funds reported $2.32B of Beam Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
  • 55 funds opened new Beam Therapeutics positions in Q1 2024 and 18 closed out, a net change of +37 holders.
  • The largest Beam Therapeutics buyer in Q1 2024 was Darwin Global Management, an estimated $66M added.
  • The largest Beam Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $132M sold.

Based on aggregated 13F filings for Q1 2024.